VANCOUVER, British Columbia, Nov. 29, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced today that Joseph Leung resigned as Chief Financial Officer and Corporate Secretary of the Company effective immediately. Ronald Li, Chief Executive Officer, stated, “On behalf of Novoheart, I would […]
Tag: Novoheart
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca
Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per year Drug developers currently lack effective humanized models for preclinical testing of targeted drug candidates in heart failure with preserved ejection fraction The collaboration aims to provide a unique solution for […]
Novoheart Holdings Inc. Reports First Quarter 2020 Financial Results
VANCOUVER, British Columbia, Nov. 19, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three months ended September 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS). Q1 2020 BUSINESS HIGHLIGHTS […]
Novoheart Grants Stock Options
VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announces that it has granted incentive stock options to purchase an aggregate of 1,150,000 common shares of the Company (the “Options”) to non-executive directors of the Company. Option Grants The Options have […]
Two new Pfizer-coauthored studies validate Novoheart’s pioneering human bioengineered heart tissues and chambers for improving drug development
September 09, 2019 00:05 ET | Source: Novoheart Holdings Inc. Novoheart seeks to revolutionize human heart tissue engineering for disease modeling and drug discovery Peer-reviewed publications feature results from the completion of two research contracts between Novoheart and Pfizer Novoheart’s proprietary MyHeartTM Platform of human bioengineered heart tissues can represent healthy as well as […]
Novoheart Holdings Inc. Reports Fourth Quarter and Fiscal 2019 Financial Results
VANCOUVER, British Columbia, Sept. 05, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and twelve months ended June 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS). Ronald Li, […]
Novoheart Holdings Inc. Completes Acquisition of Xellera Therapeutics
VANCOUVER, British Columbia, June 29, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) is pleased to announce that it has completed its previously announced acquisition (the “Acquisition”) of all of the shares of Xellera Therapeutics Limited (“XT”). As consideration for the Acquisition, Novoheart has issued […]
Novoheart Announces Appointment of New Chief Financial Officer
VANCOUVER, British Columbia, June 17, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) announced the appointment of Joseph Leung (“Joseph”) as its new Chief Financial Officer (“CFO”) and Corporate Secretary. Joseph will be replacing Dr. Camie Chan, who has been serving as the Company’s interim CFO and […]
Novoheart to Acquire Xellera Therapeutics
Xellera Therapeutics Limited will accelerate the progression of Novoheart’s current business scope Significantly enhances Novoheart’s liquidity, gaining access to approximately C$22,500,000 cash VANCOUVER, British Columbia, May 28, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced that effective on May 27, 2019, it has entered into […]
Novoheart to Generate USD $1.7m From Strategic Partnership to Build Good Manufacturing Practice Facility to Create Clinical-Grade Human Stem Cell Libraries
VANCOUVER, British Columbia, Oct. 31, 2018 (GLOBE NEWSWIRE) — Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce that it has entered into a service agreement with Xellera Therapeutics Limited, representing Phase 1 of an intended long-term strategic partnership between the companies. […]
Recent
Popular
- No commented posts yet